The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...

Shionogi has prior experience in Covid-19 drug development. In 2024, the company’s antiviral drug Xocova (ensitrelvir) received full approval in Japan, but the Phase III SCORPIO-HR trial ...

Ensitrelvir, known as Xocova ® in countries where it is approved ... public-private partnership. Shionogi also recently released preliminary results from a multicenter, randomized, double ...

Shionogi & Co., Ltd. engages in the research ... Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza ...

Earnings Call Insights: Shionogi & Co., Ltd. (OTCPK ... Growth is expected from the HIV franchise, global expansion of Xocova, and stabilization of domestic infectious disease businesses.

Founded in 1878 and based in Osaka, Japan, Shionogi is a drug-discovery-based pharmaceutical company with more than 5,500 employees and operations around the globe, including offices in the US ...

Shionogi & Co. said on Thursday it had filed for approval in Japan of its experimental COVID-19 vaccine. The move comes two days after Japanese regulators granted emergency approval for Shionogi's ...